RSS Feeds
Search

Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..10 of 13 - per page Next page
Order by
Prevention of Platinum-Based Cancer Chemotherapy Hearing Loss: Phase III Clinical Development of Sodium Thiosulphate
Prevention of Platinum-Based Cancer Chemotherapy Hearing Loss: Phase III Clinical Development of Sodium Thiosulphate More
Development of a Cellular and Animal Model for Infantile Haemangioma
Development of a Cellular and Animal Model for Infantile Haemangioma More
HC Toxin for Treating Advanced Stage Neuroblastoma: Specific Inhibition of Histone Deacetylases by HC-Toxin
HC Toxin for Treating Advanced Stage Neuroblastoma: Specific Inhibition of Histone Deacetylases by HC-Toxin More
Detection of Nup214-Abl1 Fusion in T-ALL Allows Therapeutic Intervention
Detection of Nup214-Abl1 Fusion in T-ALL Allows Therapeutic Intervention More
High-Throughput Glutathione S-Transferase (GST) Polymorphic Allele Assay Design, Especially for Paediatrics
High-Throughput Glutathione S-Transferase (GST) Polymorphic Allele Assay Design, Especially for Paediatrics More
GRASPA®: Phase II Clinical Trial for the Treatment of Recurrent Acute Lymphoblastic Leukaemia in Adult and Children
GRASPA®: Phase II Clinical Trial for the Treatment of Recurrent Acute Lymphoblastic Leukaemia in Adult and Children More
Bone Morphogenetic Protein 4 (BMP4) for Treating Advanced Stage Neuroblastoma: Therapeutic Strategy Targeted N-myc Amplified Neuroblastoma Cells
Bone Morphogenetic Protein 4 (BMP4) for Treating Advanced Stage Neuroblastoma: Therapeutic Strategy Targeted N-myc Amplified Neuroblastoma Cells More
Identification of Subgroups of Childhood Acute Leukaemia: Improved Diagnosis and Risk Classification
Identification of Subgroups of Childhood Acute Leukaemia: Improved Diagnosis and Risk Classification More
Improved Diagnosis, Risk Classification, and Outcome Prediction in High Risk B Precursor Acute Lymphoblastic Leukaemia
Improved Diagnosis, Risk Classification, and Outcome Prediction in High Risk B Precursor Acute Lymphoblastic Leukaemia More
Towards the Development of Specific Anticancer Therapies Caspase 8 Acts as a Tumour Suppressor in Neuroblastomas
Towards the Development of Specific Anticancer Therapies Caspase 8 Acts as a Tumour Suppressor in Neuroblastomas More
Displaying 1..10 of 13 - per page Next page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
US Oncology, Inc.: SWOT Analysis & Company Profile
Dec 2010 - 19 pages - $99
Pediatric Brain Tumor Consortium – Developmental Therapeutics Review – Q4 2010
Nov 2010 - 40 pages - $500
US Oncology, Inc. - SWOT Analysis
Nov 2010 - 26 pages - $125
China Pediatric Pharmaceuticals, Inc. (CPDU) - Strategic SWOT Analysis Review
May 2011 - 15 pages - $250
Light Sciences Oncology, Inc. - Product Pipeline Review - Q4 2010
Dec 2010 - 49 pages - $500
Japan: Pricing, Reimbursement and Regulatory Update
Nov 2011 - 18 pages - $1,900
Supportive Care in Oncology Market Forecast
Nov 2009 - $15,200
US Oncology, Inc. – Developmental Therapeutics Review – Q4 2010
Nov 2010 - 40 pages - $500
ZIOPHARM Oncology, Inc. – Product Pipeline Review – Q4 2010
Dec 2010 - 57 pages - $500
Southwest Oncology Group – Developmental Therapeutics Review – Q4 2010
Nov 2010 - 40 pages - $500
More Related Market Research Reports >>>

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us